Literature DB >> 20128685

Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis.

Michael Blaber1, Hyesook Yoon, Maria A Juliano, Isobel A Scarisbrick, Sachiko I Blaber.   

Abstract

A large body of emerging evidence indicates a functional interaction between the kallikrein-related peptidases (KLKs) and proteases of the thrombostasis axis. These interactions appear relevant for both normal health as well as pathologies associated with inflammation, tissue injury, and remodeling. Regulatory interactions between the KLKs and thrombostasis proteases could impact several serious human diseases, including neurodegeneration and cancer. The emerging network of specific interactions between these two protease families appears to be complex, and much work remains to elucidate it. Complete understanding how this functional network resolves over time, given specific initial conditions, and how it might be controllably manipulated, will probably contribute to the emergence of novel diagnostics and therapeutic agents for major diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128685      PMCID: PMC3047482          DOI: 10.1515/BC.2010.024

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  100 in total

1.  Identification and characterization of novel tPA- and plasminogen-binding sites within fibrin(ogen) alpha C-domains.

Authors:  G Tsurupa; L Medved
Journal:  Biochemistry       Date:  2001-01-23       Impact factor: 3.162

2.  Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4.

Authors:  T J Harvey; J D Hooper; S A Myers; S A Stephenson; L K Ashworth; J A Clements
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

3.  Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome.

Authors:  S Chavanas; C Bodemer; A Rochat; D Hamel-Teillac; M Ali; A D Irvine; J L Bonafé; J Wilkinson; A Taïeb; Y Barrandon; J I Harper; Y de Prost; A Hovnanian
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

4.  Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.

Authors:  K List; O N Jensen; T H Bugge; L R Lund; M Ploug; K Danø; N Behrendt
Journal:  Biochemistry       Date:  2000-01-25       Impact factor: 3.162

5.  Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process?

Authors:  I E Ekholm; M Brattsand; T Egelrud
Journal:  J Invest Dermatol       Date:  2000-01       Impact factor: 8.551

6.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.

Authors:  E Camerer; W Huang; S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

7.  Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region.

Authors:  L Gan; I Lee; R Smith; R Argonza-Barrett; H Lei; J McCuaig; P Moss; B Paeper; K Wang
Journal:  Gene       Date:  2000-10-17       Impact factor: 3.688

8.  Proteolytic processing of human growth hormone (GH) by rat tissues in vitro: influence of sex and age.

Authors:  M Garcia-Barros; J Devesa; V M Arce
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

9.  Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4.

Authors:  G M Yousef; A Chang; A Scorilas; E P Diamandis
Journal:  Biochem Biophys Res Commun       Date:  2000-09-16       Impact factor: 3.575

10.  Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.

Authors:  H H Heidtmann; D M Nettelbeck; A Mingels; R Jäger; H G Welker; R E Kontermann
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  8 in total

1.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

2.  Induction of complement C3a receptor responses by kallikrein-related peptidase 14.

Authors:  Katerina Oikonomopoulou; Robert A DeAngelis; Hui Chen; Eleftherios P Diamandis; Morley D Hollenberg; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

3.  Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells.

Authors:  Valérie Gratio; Céline Loriot; G Duke Virca; Katerina Oikonomopoulou; Francine Walker; Eleftherios P Diamandis; Morley D Hollenberg; Dalila Darmoul
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

4.  Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact.

Authors:  Maroulio Talieri; Marina Devetzi; Andreas Scorilas; Eleana Pappa; Nikolaos Tsapralis; Ioannis Missitzis; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-02-21

Review 5.  Protease-armed bacteria in the skin.

Authors:  Joanna Koziel; Jan Potempa
Journal:  Cell Tissue Res       Date:  2012-02-23       Impact factor: 5.249

Review 6.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

Review 7.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

8.  Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Evangelia Prosnikli; Gregory P Evangelatos; Evangelia Livaniou
Journal:  Chem Cent J       Date:  2012-12-05       Impact factor: 4.215

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.